DV
Dividend Vision

KURA — Kura Oncology, Inc.

Kura Oncology, Inc. (KURA)

Total return is -27.6% over the past 10.9 years, 392.8 points behind SPY at 365.2%. Its deepest 1-year drawdown was 39.0%.

This is a single-stock equity holding in Kura Oncology, Inc., a biopharmaceutical company focused on oncology drug development, rather than a diversified ETF. The holding does not currently pay distributions and carries no listed expense ratio, as it represents direct equity ownership in the company. This security appeals primarily to investors seeking exposure to the oncology sector and early-stage biotech development, rather than those focused on dividend income.

KURA key facts

Asset type
Stock
Asset class
Equity
Inception date
09/16/2015
Distribution frequency
None
Last close
$10.86
Market cap
$966,112,256
Average volume
1886011.0
Beta
0.381
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.37